Summary of the Conference Call on the Innovative Drug Industry Chain Industry Overview - The innovative drug industry is expected to show signs of recovery in 2024 and 2025, with a significant increase in BD transaction amounts indicating a rebound in market activity [1][3] - The growth investment opportunities are primarily driven by the launch and commercialization of blockbuster drugs, leading to increased CDMO outsourcing orders, particularly in the expanding markets for peptide drugs (e.g., teriparatide) and GLP-1 weight loss medications [1][3] Key Companies and Growth Opportunities - **WuXi AppTec** is highlighted as a beneficiary due to its ample production capacity, particularly in the peptide sector [1][4] - **Zhaoyan New Drug** is noted for its improving profitability margins, driven by the rebound in the price of experimental monkeys [1][3] - **Tigermed** is expected to see improvements in profitability due to better order structures, which will manifest in 2026 [1][3] - **Boteng Co.** is set to improve its gross margin and capacity utilization due to the recovery of core orders from major clients [2][4] Market Trends and Projections - The peptide and ADC (antibody-drug conjugate) markets are identified as two critical growth segments, with the ADC market projected to maintain a compound annual growth rate (CAGR) of over 30% in the coming years [1][4] - The sales growth of teriparatide has exceeded expectations, positively impacting the performance of related CDMO companies [1][4] Investment Cycle Insights - The innovative drug industry is currently in a new upward cycle, with historical investment cycles averaging 3-4 years. The low point of the current cycle was in 2022, with a gradual recovery expected in 2024 and 2025 [3][4] - The total BD transaction amount in 2025 is anticipated to significantly exceed that of 2024, reflecting a warming market sentiment [3][4] Additional Considerations - The clinical CRO sector, represented by Zhaoyan New Drug, is showing signs of marginal improvement due to price rebounds, while Tigermed's order structure improvements are expected to enhance profitability [1][3][4] - The focus on companies with strong production capacity and stable supply capabilities is crucial for capitalizing on the upcoming growth in the innovative drug sector [1][4]

Group 1 - The core viewpoint of the news is that the innovative drug sector is experiencing a strong rally, with significant gains in stocks such as Huyou Pharmaceutical, King’s Ray Biotechnology, and Nuotai Biotechnology, which have all risen over 9% [1] - The Tianhong Innovative Drug ETF (517380) has seen a rise of over 3.5% in early trading, reaching a new high in this round of rebound, reflecting the overall market's positive sentiment towards innovative drugs [1] - Analysts predict that 2025 will mark a year of explosive growth for China's innovative drug industry, driven by three core factors: the continuous landing of significant BD transactions, leading companies turning profitable, and an improving policy environment [1] Group 2 - The Chinese innovative drug market is projected to exceed 2 trillion yuan by 2030, with a compound annual growth rate of 24.1% [1] - There is an increasing demand for low-cost, high-quality drugs globally, prompting multinational pharmaceutical companies to seek partnerships with Chinese firms for more cost-effective innovative drug assets [1] - The release of multiple clinical data during the ASCO conference has brought additional attention and catalysts to the innovative drug sector [1] Group 3 - The Tianhong Innovative Drug ETF (517380) has achieved a cumulative increase of over 27% this year, leading all industry ETFs in market performance, outperforming the second-place ETF by approximately 10 percentage points [2] - Investors interested in the innovative drug sector may consider focusing on linked funds, specifically Class A (014564) and Class C (014565) [3]

Core Viewpoint - The Hong Kong innovative drug sector shows signs of stabilization after a recent high and subsequent pullback, with expectations for explosive growth in the industry by 2025 driven by key factors [1] Group 1: Industry Growth Drivers - The innovative drug sector in China is expected to enter at least a three-year upward cycle due to three core factors: continuous high upfront payments for significant BD transactions, leading companies turning profitable by 2025, and an improving policy environment for innovative drugs [1] - The market size for China's innovative drugs is projected to exceed 2 trillion yuan by 2030, with a compound annual growth rate (CAGR) of 24.1% [1] Group 2: Market Dynamics - As Chinese innovative drug companies enhance their R&D capabilities, multinational pharmaceutical companies are actively seeking partnerships with local firms to acquire cost-effective innovative drug assets [1] - The release of multiple clinical data during the ASCO conference has attracted more attention and catalyzed interest in the innovative drug sector [1] Group 3: Investment Opportunities - Investors optimistic about the innovative drug sector can leverage products like the Hang Seng Innovative Drug ETF (159316) and the Hong Kong Stock Connect Medical ETF (513200) to capitalize on the growth opportunities in innovative drug companies [1] - The Hang Seng Innovative Drug ETF (159316) is the first ETF tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Index, focusing on companies involved in innovative drug research, development, and production [2] - The Hong Kong Stock Connect Medical ETF (513200) tracks the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index, covering key areas such as innovative drugs, medical devices, and medical services, with a current size of 2.65 billion yuan [2]